Imaging can show changes in cardiac structure that symptom questionnaires cannot. It can also introduce a selected analysis population when only some participants have usable scans at both visits. Primary substudy
What the images showed
Of 175 SUMMIT participants with baseline cardiac MRI, 106 had adequate paired baseline and 52-week scans. The paired groups contained 50 tirzepatide and 56 placebo recipients. Left ventricular mass, the prespecified primary imaging endpoint, decreased relative to placebo. Paracardiac fat also decreased; this category combined epicardial and pericardial fat. Changes in ventricular mass correlated with weight change. Primary report
Our appraisal: keep the denominator and anatomy visible
The imaging result should not be presented as if every parent-trial participant contributed paired scans. A complete assessment needs reasons for missing or inadequate follow-up images and comparisons between included and excluded participants. Treatment assignment alone does not make a complete-case subset immune to selection concerns.
Anatomical labels matter. Paracardiac fat in this report is broader than epicardial fat alone. Renaming the combined compartment can imply a more specific tissue effect than the investigators actually measured.
Structural change is not automatically proof of the mechanism responsible for clinical improvement. A correlation with weight change can support a hypothesis, but it does not isolate cause and effect or establish that reducing ventricular mass mediated fewer heart-failure events.
Nor should ventricular mass be confused with ejection fraction. They describe different cardiac features. A favorable result for one does not establish a corresponding change in the other unless it was measured and supported.
This substudy adds an imaging perspective to SUMMIT's clinical and biomarker publications. The reports share a trial lineage and should not be counted as separate independent confirmations. Before release, review should examine image-reading procedures, missing-data handling, prespecified analyses, and secondary-endpoint multiplicity. The resulting interpretation should remain specific to the studied population and measured structural outcomes.
Frequently asked questions
Did every baseline scan have an adequate follow-up partner?
No.
How many participants had paired usable scans?
Was ventricular mass the primary imaging endpoint?
Yes.
Is paracardiac fat synonymous with epicardial fat alone?
No.
Does correlation with weight establish mediation?
No.
Is ventricular mass the same as ejection fraction?
No.
Is this a separate independent trial from SUMMIT?
No; it is an imaging substudy.